Leerink Partners initiated coverage on Summit Therapeutics with a new price target

6/11/25 7:54:51 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Leerink Partners initiated coverage of Summit Therapeutics with a rating of Underperform and set a new price target of $12.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SMMT

Date	Price Target	Rating	Analyst
6/11/2025	$12.00	Underperform	Leerink Partners
3/26/2025	$23.00 → $35.00	Neutral → Buy	Citigroup
3/21/2025		Overweight	Cantor Fitzgerald
3/12/2025	$30.00	Outperform	Evercore ISI
2/28/2025	$42.00	Buy	Goldman
1/8/2025	$35.00	Buy	Truist
12/11/2024	$30.00	Overweight	Wells Fargo
12/6/2024	$31.00	Buy	Jefferies